ACAD (ACAD) Stock Price & Analysis
ACAD (ACAD) rose 0.57% to USD 28.02 as of September 8, 2026 at 05:01 UTC, according to Nexqual real-time market data.
ACAD last closed at USD 28.02; the session ranged USD 27.65–28.19 on volume of 1,682,950 shares. Market capitalization is —, with a 52-week range of USD 19.69–30.96 (NMS). Source: Nexqual, September 8, 2026 at 05:01 UTC.
Key Statistics (as of September 8, 2026 at 05:01 UTC)
| Price | USD 28.02 |
|---|---|
| Change | ▲ 0.57% (up) |
| Previous Close | USD 28.02 |
| Open | USD 28.02 |
| Day Range | USD 27.65 – 28.19 |
| 52-Week Range | USD 19.69 – 30.96 |
| Volume | 1,682,950 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ACAD)
Nexqual's technical model rates ACAD "BUY" based on 4 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.13 (neutral) |
| vs SMA50 | Above (USD 27.29) |
| MACD | 0.4 (positive) |
From ACAD's Latest SEC 10-K Filing (filed 2026-02-26)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | USD 22.5 | ▼ 3.06% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 266.11 | ▼ 0.48% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 66.53 | ▼ 0.66% |
| CLDX | Celldex Therapeutics, Inc. | USD 39.68 | ▲ 0.51% |
| EXEL | Exelixis, Inc. | USD 59.01 | ▲ 0.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:01 UTC. This page is informational and not investment advice.